Company intelligence / Profile preview

Yunnan Sunway Pharmaceutical

Kunming, Yunnan, Chinawww1.hkexnews.hk ↗

Ownership: Private
Development stage: Other

Overview

SINOWAY markets several established drugs including amlodipine mesylate (hypertension), Kangfuxin (gastrointestinal and wound indications), and Ganlong Capsule (chronic hepatitis), as well as Periplaneta americana extract-based products. The company has developed a novel immunotoxin (SN-001) in early preclinical development.

Therapeutic areas: DermatologyGastroenterologyRare DiseasesInfectious DiseasesCardiovascularHematology
Modalities: Small moleculeBiologicMonoclonal antibodyImmunotoxinNatural product
Industry: Biotech

Drug pipeline

1 asset

danqi tablets

Unknown

Partnerships

Shanghai Jiaotong University (immunotoxin development)Jecho Laboratories, Inc. (Periplaneta americana research)Over 20 pharmacy chains in China for distribution

Beyond the preview

Go deeper on Yunnan Sunway Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yunnan Sunway Pharmaceutical.

Explore the full profile